IP Library Granted Patent US 9,585,920
Granted Patent B2
US 9,585,920 · App. 15/228,454 · Granted Mar 7, 2017

Method and system for treating cancer cachexia

Inventors: Katherine Rose Kovarik (Englewood, CO); Joseph E. Kovarik (Englewood, CO)
A61K35/74A61K9/0014A61K9/0034A61K9/0043A61K9/0053A61K31/58A61K35/741A61K35/742A61K35/745A61K35/747A61K38/1758A61K39/35A61K39/395A61K45/06C07K16/00A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,585,920
App. No.
15/228,454
Granted
Mar 7, 2017
Kind
B2
Abstract

Various embodiments of the present invention are directed to the field of Oncology, and in particular, embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, p53 protein, etc., is employed to address cancerous conditions. In several embodiments, the administration of such beneficial bacteria and microbes to an individual's microbiome invokes either an active (or a passive) immune response to destroy, weaken or render less invasive certain cancerous cells, and preferably maintains muscle tissue to combat cancer cachexia.

Claims (17)

1. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce one of tomatidine and p53 and wherein the cancer is bladder cancer or colorectal cancer.

2. The method of claim 1 , wherein said bacillus calmette-guerin produces both tomatidine and p53.

3. The method of claim 1 , wherein the bacillus calmette-guerin has been modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system to produce at least one of tomatidine and p53.

4. The method of claim 1 , wherein the cancer is colorectal cancer.

5. The method of claim 1 , wherein the bacillus calmette-guerin is further adapted to produce rapamycin.

6. The method of claim 1 , wherein said method maintains or increases the muscle mass of an individual suffering from cancer, and wherein the bacterial composition has been modified via a CRISPR-Cas system to express tomatidine.

7. The method of claim 1 , wherein the cancer is bladder cancer.

8. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adapted to produce tomatidine and wherein the cancer is bladder cancer or colorectal cancer.

9. The method of claim 8 , wherein the cancer is bladder cancer.

10. The method of claim 8 , wherein the cancer is colorectal cancer.

11. The method of claim 8 , wherein the bacillus calmette-guerin is further adapted to produce rapamycin.

12. The method of claim 8 , wherein said method maintains or increases the muscle mass of an individual suffering from cancer, and wherein the bacterial composition has been modified via a CRISPR-Cas system to express tomatidine.

13. A method of treating cancer cachexia in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a composition comprising bacillus calmette-guerin adaptead to produce p53.

14. The method of claim 13 , wherein the cancer is bladder cancer.

15. The method of claim 13 , wherein the cancer is colorectal cancer.

16. The method of claim 13 , wherein the bacillus calmette-guerin is further adapted to produce rapamycin.

17. The method of claim 13 , wherein said method maintains or increases the muscle mass of an individual suffering from cancer, and wherein the bacterial composition has been modified via a CRISPR-Cas system to express tomatidine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: KOVARIK, JOE
To: SEED HEALTH, INC.
Reel/Frame 059690/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: KOVARIK, JOSEPH E
To: KOVARIK, JOSEPH E.
Reel/Frame 057819/0661 →
Continuity (24)
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 15200210 · Jul 1, 2016
Continuation 14283459 · May 21, 2014
Continuation 15228454
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 62296186 · Feb 17, 2016
Provisional Application 62278046 · Jan 13, 2016
Provisional Application 62277571 · Jan 12, 2016
Provisional Application 62277568 · Jan 12, 2016
Provisional Application 62275341 · Jan 6, 2016
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62260906 · Nov 30, 2015
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 61439652 · Feb 4, 2011
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62387405 · Dec 24, 2015
Related Publication 20160339064A1 · Nov 24, 2016